Aegis Maintains Buy on Valeant (VRX); One-Time Items Don't Reflect True Operations

October 31, 2013 2:14 PM

Aegis Capital maintains a Buy rating and $140 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results issued earlier ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found